Can New Hemostatic Dressings Facilitate Sharp Debridement In High-Risk Patients?
- Volume 22 - Issue 7 - July 2009
- 14461 reads
- 0 comments
The lower overall costs associated with chitosan-based hemostatic wound dressings also make the bandages advantageous in terms of dealing with possible reimbursement issues. The Office of the Inspector General has seen a dramatic increase in the number of Medicare claims submitted for surgical excisional wound debridement (CPT code 11042). In addition, with the advent of pay for performance measures, the Centers for Medicaid and Medicare Services (CMS) recently announced that it will no longer pay hospitals for additional costs associated with treating patients for certain hospital-acquired infections. The safety, efficacy and antibacterial indications of these bandages make them an advantageous choice in the stringent reimbursement environment.
Chitosan-based hemostatic dressings, such as the HemCon Bandage, offer a safe, cost-effective alternative to operative debridement for deep or superficial wounds in non-operative or coagulopathic patients. These bandages allow specialists to perform more sharp debridements at the bedside, increase patient comfort and improve healing outcomes. With this new wound care technology, patients with hazardous comorbidities can have unprecedented access to convenient, safer and more comfortable bedside debridement.
Dr. Schierle is affiliated with the Division of Plastic and Reconstructive Surgery, Department of Surgery, at the Northwestern University Feinberg School of Medicine.
Ms. Krol is affiliated with the Division of Plastic and Reconstructive Surgery, Department of Surgery, at the Northwestern University Feinberg School of Medicine.
Dr. Steinberg is an Assistant Professor in the Department of Plastic Surgery at the Georgetown University School of Medicine in Washington, D.C. Dr. Steinberg is a Fellow of the American College of Foot and Ankle Surgeons.
For further reading, see “Assessing Debridement Options For Diabetic Wounds” in the March 2007 issue of Podiatry Today.
1. Schierle CF, Krol J, Galiano RD. Maximizing bedside debridement utilizing chitosan-based hemostatic dressings. Abstract, Diabetic Foot Global Conference 2009, Los Angeles, March 2009.